Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of British Columbia
$105,000.00
Development of oral child-friendly formulations for the maintenance therapy in childhood acute lymphoblastic leukemia
FY 2016-17
Summary
Durable remissions in children with acute lymphoblastic leukemia (ALL) require a 2-to 3-year maintenance therapy that includes daily or weekly home administration of oral 6-mercaptopurine, methotrexate, and prednisone. The current clinical practice and available drug formulations are not truly child-friendly. As a result, medication adherence is poor, leading to an increased relapse rate. This project is aimed at developing child-friendly formulations for these drugs to improve medication adherence and ultimately, the therapeutic outcome for children suffering from ALL.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367821
Name
Tang Wei-Lun
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Development of oral child-friendly formulations for the maintenance therapy in childhood acute lymphoblastic leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Anticancer Drug Delivery; E-Tongue Technology; Lipid Nanoparticles; Oral Pediatric Formulation; Oro-Dispersible Formulation
Abstract
Durable remissions in children with acute lymphoblastic leukemia (ALL) require a 2-to 3-year maintenance therapy that includes daily or weekly home administration of oral 6-mercaptopurine, methotrexate, and prednisone. The current clinical practice and available drug formulations are not truly child-friendly. As a result, medication adherence is poor, leading to an increased relapse rate. This project is aimed at developing child-friendly formulations for these drugs to improve medication adherence and ultimately, the therapeutic outcome for children suffering from ALL.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tang, Wei-Lun
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
